MICROVASCULAR THERAPEUTICS, INC

Microvascular Therapeutics (MVT) is a clinical-stage biotechnology company headquartered in Tucson, Arizona, that specializes in the development of proprietary microbubble and nanobubble technologies to advance ultrasound diagnostic imaging and therapy. The company's core platform utilizes patented microbubble formulations, such as its lead candidate CardiSon (MVT-100), which are engineered to serve as high-performance ultrasound contrast agents. Beyond traditional imaging, MVT is expanding its technology into the field of theranostics, developing nanobubbles for image-guided therapeutic applications including non-thermal tumor ablation, sonothrombolysis for blood clots, and drug delivery platforms for conditions like Alzheimer's disease and various cancers.

These innovations aim to address significant limitations in current clinical practice, such as the need for temperature-controlled storage and the adverse side effects associated with legacy contrast agents. By creating stable, versatile microbubble platforms, MVT seeks to improve patient management and clinical outcomes in cardiology, neurology, and oncology. The company supports its development pipeline through strategic partnerships, such as its collaboration with Cordance Medical for blood-brain barrier applications, and has secured funding from both federal agencies like the NIH and NCI and private institutional investors to advance its clinical-stage programs.